New recommendations move noncore shots to shared clinical decision-making, but a court stay keeps day-to-day pharmacy practice unchanged.

A phase 4 study found that a suzetrigine-based multimodal pain regimen provided favorable postoperative pain control, with 76.1% of patients recovering without opioid rescue medication.

A first-in-class RNA degrader targeting MYC mRNA showed preclinical antimyeloma activity, offering a potential new strategy for targeting a historically difficult-to-drug driver of multiple myeloma.

Incrementalism is out of favor, and a wholesale move toward professional judgment is underway.

New trials explore glucagon-like peptide-1 receptor agonists for alcohol, nicotine use disorder, and smoking cessation.

Oncology pharmacists unite care teams like World Cup midfielders—coordinating safe care and supporting patients through hope, setbacks, and dignity.